All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Security
Security
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

Medipost's Cartistem Begins U.S. Phase 3, Doses First Patient

5h agoen

Source

Seoul Economic DailyMedipost's Cartistem Begins U.S. Phase 3, Doses First Patientsedaily.com
Snippet from the RSS feed
Medipost has dosed its first patient in the U.S. Phase 3 trial of Cartistem, its knee osteoarthritis stem cell therapy, targeting 300 patients across 70+ sites in the U.S. and Canada.

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.